卵巢癌组织中生存素的表达及临床意义的Meta分析  

Expression and clinical significance of Survivin in tissues of ovarian cancer:A Meta-analysis

作　　者：龚钿 赵红利[1] 王建华[1] 杨琴[1] Gong Tian;Zhao Hongli;Wang Jianhua;Yang Qin(Department of Obstetrics and Gynecology,Meishan People's Hospital,Sichuan Meishan 620100,China)

机构地区：[1]眉山市人民医院妇产科

出　　处：《现代肿瘤医学》2019年第20期3682-3689,共8页Journal of Modern Oncology

基　　金：四川省卫生和计划委员会资助项目(编号:J20160301)

摘　　要：目的:系统评价卵巢癌组织中生存素(Survivin)的表达水平及其与临床病理特征的关系。方法:计算机检索各种数据库,寻找与本研究相关的国内外文献,搜集卵巢癌组织中Survivin表达及其与临床病理特征关系的病例-对照研究。根据本研究要求进行筛选,排除不适合文献,对各项数据进行总结,利用计算机软件进行统计分析,最终获得结论。结果:纳入30个研究,其中卵巢癌患者1 472例,卵巢良性病变患者663例,正常对照组371例。Meta分析结果显示:Survivin在卵巢癌组和正常对照组[OR=33.70,95%CI(21.41,53.05),P<0.000 01]、卵巢癌组和卵巢良性病变组[OR=12.17,95%CI(9.55,15.53),P<0.000 01]、临床分期Ⅰ-Ⅱ期组与Ⅲ-Ⅳ期组[OR=0.16,95%CI(0.12,0.22),P<0.000 01]、临床分级G1-G2级组与G3级组[OR=0.19,95%CI(0.14,0.26),P<0.000 01]、伴淋巴结转移组和无淋巴结转移组[OR=5.89,95%CI (2.37,14.66),P=0.000 1]、伴腹水组和无腹水组[OR=5.63,95%CI(1.64,19.28),P=0.006]表达差异均有统计学意义。但在卵巢癌患者年龄>50岁组和≤50岁组[OR=0.82,95%CI(0.47,1.43),P=0.47]表达差异无统计学意义。结论:Survivin表达与卵巢癌及其临床病理特征明显相关,由此可见其有可能参与卵巢癌的整个过程当中。由于所选择文献相对有限,结论仍需进一步验证,希望有更大样本研究参与其中,获得更可靠结果。Objective:To systematically evaluate the expression of Survivin in ovarian cancer and its relationship with clinicopathological features.Methods:Various databases were searched by computer.Domestic and foreign literatures related to this study were searched,and case-control studies on the relationship between Survivin expression and clinicopathological features in ovarian cancer tissues were collected.According to the requirements of this study,unsuitable literatures were excluded.various data were summarized.Statistical analysis was did by using computer software.Results:Thirty studies were included,of which 1 472 were ovarian cancer patients,663 were benign ovarian lesions,and 371 were normal controls.Meta-analysis showed that there was significant difference for Survivin in ovarian cancer and normal control group [OR=33.70,95%CI(21.41,53.05),P<0.000 01],ovarian cancer group and benign ovarian disease group [OR=12.17,95%CI( 9.55,15.53),P<0.000 01],clinical stages I-II and III-IV group [OR=0.16,95%CI(0.12,0.22),P<0.000 01],clinical grade G1-G2 group and G3 group [OR=0.19,95%CI(0.14,0.26),P<0.000 01],lymph node metastasis group and no lymph node metastasis group [OR=5.89,95%CI(2.37,14.66),P=0.000 1],ascites group and ascites group[OR=5.63,95%CI(1.64,19.28),P=0.006].However,there was no significant difference in the expression of ovarian cancer patients> 50 years old group and ≤50 years old group [OR=0.82,95%CI(0.47,1.43),P=0.47].Conclusion:The expression of Survivin is significantly associated with ovarian cancer and its clinicopathological features.It can be seen that it may be involved in the entire process of ovarian cancer.Since the selected literature is relatively limited,the conclusions still need to be further verified.It is hoped that more sample studies will be involved to obtain more reliable results.

关 键 词：SURVIVIN 卵巢癌 META分析 病例-对照研究 

分 类 号：R737.31[医药卫生—肿瘤]